NDA[removed]S-008 NDA[removed]S-010 Page 5 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed

First Page		Document Content
Date: 2014-09-09 11:11:56 Ophthalmology Bimatoprost Eyelash Allergan Ocular hypertension Blepharitis Prostaglandin analogue Eye surgery Eyelid Medicine Prostaglandins Anatomy		NDA[removed]S-008 NDA[removed]S-010 Page 5 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed Add to Reading List Source URL: www.accessdata.fda.gov Download Document from Source Website File Size: 345,56 KB Share Document on Facebook

	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TRAVATAN Z® (travoprost ophthalmic solution% safely and effectively. See full prescribing information for TR DocID: 1ova7 - View Document
	PIPELINE WATCH Latanoprost SPC ends in top EU markets n mid-January, Pfizer’s blockbuster treatment for glaucoma and ocular hypertension, Xalatan (latanoprost), loses supplementary protection certificate (SPC) exclusi DocID: 1ni1B - View Document
	TRUSOPT Ped data PAR DocID: 1aNXe - View Document
	ISSUEInside this issue: DocID: 18TI5 - View Document
	Fact Sheet Ocular Hypertension (OHT) Ocular hypertension means the pressure inside the eye, intraocular pressure (IOP), is elevated above the range considered normal, usually greater than 21mm Hg. However, despite having DocID: 17Jju - View Document